Intellipharmaceutics International Inc (IPCI):企業の財務・戦略的SWOT分析

◆英語タイトル:Intellipharmaceutics International Inc (IPCI) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA8012452
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月5日
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Intellipharmaceutics International Inc (IPCI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Intellipharmaceutics International Inc (Intellipharmaceutics) is a research based pharmaceutical company that develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company’s portfolio encompasses controlled-release candidates for management of neuropathic pain, attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder and panic disorder; type 2 diabetes; and stomach ulcers. It offers a comprehensive range of pre-formulation studies, design, and development through to regulatory approval. The company’s drug delivery systems and pipeline candidates are based on its Hypermatrix, a proprietary multidimensional controlled-release drug delivery technology. Intellipharmaceutics’ is headquartered in Toronto, Ontario, Canada.

Intellipharmaceutics International Inc Key Recent Developments

Oct 10,2017: Intellipharmaceutics Announces Third Quarter 2017 Results
Sep 01,2017: Intellipharmaceutics appoints new Chief Financial Officer
Sep 01,2017: Intellipharmaceutics Appoints New Chief Financial Officer
Aug 08,2017: Intellipharmaceutics Announces Resignation of CFO
Jul 11,2017: Intellipharmaceutics Announces Second Quarter 2017 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Intellipharmaceutics International Inc – Key Facts 5
Intellipharmaceutics International Inc – Key Employees 6
Intellipharmaceutics International Inc – Key Employee Biographies 7
Intellipharmaceutics International Inc – Major Products and Services 8
Intellipharmaceutics International Inc – History 9
Intellipharmaceutics International Inc – Locations And Subsidiaries 10
Head Office 10
Other Locations & Subsidiaries 10
Section 2 – Company Analysis 11
Intellipharmaceutics International Inc – Business Description 11
R&D Overview 11
Intellipharmaceutics International Inc – SWOT Analysis 12
SWOT Analysis – Overview 12
Intellipharmaceutics International Inc – Strengths 12
Intellipharmaceutics International Inc – Weaknesses 13
Intellipharmaceutics International Inc – Opportunities 14
Intellipharmaceutics International Inc – Threats 15
Intellipharmaceutics International Inc – Key Competitors 16
Section 3 – Company Financial Ratios 17
Financial Ratios – Capital Market Ratios 17
Financial Ratios – Annual Ratios 18
Performance Chart 20
Financial Performance 20
Financial Ratios – Interim Ratios 21
Financial Ratios – Ratio Charts 22
Section 4 – Company’s Lifesciences Financial Deals and Alliances 23
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 23
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 24
Intellipharmaceutics International Inc, Recent Deals Summary 25
Section 5 – Company’s Recent Developments 26
Oct 10, 2017: Intellipharmaceutics Announces Third Quarter 2017 Results 26
Sep 01, 2017: Intellipharmaceutics Appoints New Chief Financial Officer 28
Aug 08, 2017: Intellipharmaceutics Announces Resignation of CFO 29
Jul 11, 2017: Intellipharmaceutics Announces Second Quarter 2017 Results 30
May 26, 2017: Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement 32
Apr 11, 2017: Intellipharmaceutics Announces First Quarter 2017 Results 33
Mar 16, 2017: Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI” 36
Feb 10, 2017: Intellipharmaceutics Announces 2016 Year End Results 37
Oct 13, 2016: Intellipharmaceutics Announces Third Quarter 2016 Results 40
Jul 13, 2016: Intellipharmaceutics Announces Second Quarter 2016 Results 42
Section 6 – Appendix 44
Methodology 44
Ratio Definitions 44
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Intellipharmaceutics International Inc, Key Facts 5
Intellipharmaceutics International Inc, Key Employees 6
Intellipharmaceutics International Inc, Key Employee Biographies 7
Intellipharmaceutics International Inc, Major Products and Services 8
Intellipharmaceutics International Inc, History 9
Intellipharmaceutics International Inc, Subsidiaries 10
Intellipharmaceutics International Inc, Key Competitors 16
Intellipharmaceutics International Inc, Ratios based on current share price 17
Intellipharmaceutics International Inc, Annual Ratios 18
Intellipharmaceutics International Inc, Annual Ratios (Cont...1) 19
Intellipharmaceutics International Inc, Interim Ratios 21
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 23
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 24
Intellipharmaceutics International Inc, Recent Deals Summary 25
Currency Codes 44
Capital Market Ratios 44
Equity Ratios 45
Profitability Ratios 45
Cost Ratios 46
Liquidity Ratios 46
Leverage Ratios 47
Efficiency Ratios 47

★海外企業調査レポート[Intellipharmaceutics International Inc (IPCI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Millennium & Copthorne Hotels Plc:戦略・SWOT・企業財務分析
    Millennium & Copthorne Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary Millennium & Copthorne Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Boston Scientific Corporation:企業のM&A・事業提携・投資動向
    Boston Scientific Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Boston Scientific Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Saint-Gobain Weber GmbH:企業の戦略・SWOT・財務情報
    Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report Summary Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Northfork Electric Cooperative Inc:企業の戦略的SWOT分析
    Northfork Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Votorantim SA:企業の戦略的SWOT分析
    Votorantim SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Hitec Power Protection BV:企業の戦略的SWOT分析
    Hitec Power Protection BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • VAALCO Energy Inc (EGY):石油・ガス:M&Aディール及び事業提携情報
    Summary VAALCO Energy, Inc. (VAALCO) is an upstream oil and gas company. It acquires, explores, develops and produces crude oil and natural gas from assets. The company conducts the exploration activities as operator in Gabon and as a non-operator in Equatorial Guinea, West Africa. The company’s ass …
  • Orpak Systems Limited:企業の戦略的SWOT分析
    Orpak Systems Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Raley’s Family of Fine Stores:企業の戦略的SWOT分析
    Raley's Family of Fine Stores - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Clean TeQ Holdings Ltd (CLQ):企業の財務・戦略的SWOT分析
    Summary Clean TeQ Holdings Ltd (Clean TeQ) is a clean technology company that offers air pollution control solutions using biotechnology-based processes. The company provides water treatment products such as advanced separations, advanced oxidation, encapsulated bacteria, continuous ionic filtration …
  • Oriental Food Industries Holdings Berhad:企業の戦略・SWOT・財務情報
    Oriental Food Industries Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Oriental Food Industries Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Tsumura & co (4540):製薬・医療:M&Aディール及び事業提携情報
    Summary Tsumura & co (Tsumura) is a traditional pharmaceutical products company, which undertakes the manufacturing and sale of Kampo extract intermediates and granular Kampo formulations. Its product portfolio includes a range of prescription Kampo products, other pharmaceuticals, over-the-counter …
  • Verdezyne Inc-製薬・医療分野:企業M&A・提携分析
    Summary Verdezyne Inc (Verdezyne) is an industrial biotechnology company that develops and produces chemicals from renewable and non-food sources. The company’s products include adipic acid, dodecanedioic acid and sebacic acid. Its products are used in production of toothbrush bristles and fishing l …
  • Telephonics Corp:企業の戦略的SWOT分析
    Telephonics Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • NovAliX SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary NovAliX SAS (NovAliX) is a contract research organization that offers outsourcing and insourcing research services for drug discovery. The organization provides chemical biology services such as chemistry, biophysics, drug discovery and protein purification services. Its biophysics services …
  • Source BioScience Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Source Bioscience Ltd (Source BioScience), a subsidiary of Sherwood Holdings Ltd is a provider of laboratory products and services. The company offers life science research, clinical product, and controlled environment products. Its life science research products include antibodies, clones, …
  • Ignyta Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). …
  • Hemanext:医療機器:M&Aディール及び事業提携情報
    Summary Hemanext, formerly New Health Sciences Inc, is a medical technology company that develops blood storage systems. The company offers an anaerobic storage system that minimizes oxidative damage to red blood cells in storage and delivers physiologic, therapeutic, and fresher red blood cell than …
  • CUB Pty Ltd:企業の戦略的SWOT分析
    CUB Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kadimastem Ltd (KDST):製薬・医療:M&Aディール及び事業提携情報
    Summary Kadimastem Ltd (Kadimastem) is a clinical stage biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells (differentiated cells) and glia restricted progenito …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆